Pasar al contenido principal

Papel de mediadores inflamatorios y antinflamatorios en el daño cardiovascular asociado a diversas e

IJCI-2017-31399

•
Nombre agencia financiadora Agencia Estatal de Investigación
Acrónimo agencia financiadora AEI
Programa Programa Estatal de Promoción del Talento y su Empleabilidad en I+D+i
Subprograma Subprograma Estatal de Incorporación
Convocatoria Juan de la Cierva Incorporación
Año convocatoria 2017
Plan Estatal 2017-2020 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario UNIVERSIDAD AUTONOMA DE MADRID

Resultados relacionados

Resultados totales (Incluyendo duplicados): 4
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Microsomal prostaglandin E synthase-1 is involved in the metabolic and cardiovascular alterations associated with obesity

  • Ballesteros-Martínez, Constanza
  • Rodrigues-Díez, Raquel
  • Beltrán, Luis M.
  • Moreno-Carriles, Rosa
  • Martínez-Martínez, Ernesto
  • González-Amor, María
  • Martínez-González, José
  • Rodríguez-Sinovas, Cristina
  • Cachofeiro, Victoria
  • Salaices, Mercedes
  • Briones, Ana M.
Background and Purpose: Microsomal prostaglandin E synthase-1 (mPGES-1) is an inducible isomerase responsible for prostaglandin E production in inflammatory conditions. We evaluated the role of mPGES-1 in the development and the metabolic and cardiovascular alterations of obesity. Experimental Approach: mPGES-1 and mPGES-1 mice were fed with normal or high fat diet (HFD, 60% fat). The glycaemic and lipid profile was evaluated by glucose and insulin tolerance tests and colorimetric assays. Vascular function, structure and mechanics were assessed by myography. Histological studies, q-RT-PCR, and western blot analyses were performed in adipose tissue depots and cardiovascular tissues. Gene expression in abdominal fat and perivascular adipose tissue (PVAT) from patients was correlated with vascular damage. Key Results: Male mPGES-1 mice fed with HFD were protected against body weight gain and showed reduced adiposity, better glucose tolerance and insulin sensitivity, lipid levels and less white adipose tissue and PVAT inflammation and fibrosis, compared with mPGES-1 mice. mPGES-1 knockdown prevented cardiomyocyte hypertrophy, cardiac fibrosis, endothelial dysfunction, aortic insulin resistance, and vascular inflammation and remodelling, induced by HFD. Obesity-induced weight gain and endothelial dysfunction of resistance arteries were ameliorated in female mPGES-1 mice. In humans, we found a positive correlation between mPGES-1 expression in abdominal fat and vascular remodelling, vessel stiffness, and systolic blood pressure. In human PVAT, there was a positive correlation between mPGES-1 expression and inflammatory markers. Conclusions and Implications: mPGES-1 inhibition might be a novel therapeutic approach to the management of obesity and the associated cardiovascular and metabolic alterations., Ministerio Ciencia e Innovación. Programa Juan de la Cierva, Grant/Award Number: IJCI-2017-31399; Comunidad de Madrid, Grant/Award Number: B2017/BMD-3676AORTASANA, FEDER-a way to build Europe;Fondo Europeo de Desarrollo Regional, Grant/Award Number: SAF2016-80305P; Ministeriode Ciencia e Innovacion, Grant/AwardNumber: FIS PI18/0257
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Resolvin D2 Attenuates Cardiovascular Damage in Angiotensin II-Induced Hypertension

  • Díaz del Campo, Lucía S.
  • García-Redondo, Ana B.
  • Rodríguez, Cristina
  • Zaragoza, Carlos
  • Duro-Sánchez, Santiago
  • Palmas, Francesco
  • Benito-Bueno, Ángela de
  • Socuéllamos, Paula G.
  • Peraza, Diego A.
  • Rodrigues-Díez, Raquel
  • Valenzuela, Carmen
  • Dalli, Jesmond
  • Salaices, Mercedes
  • Briones, Ana M.
[Background]: Resolution of inflammation is orchestrated by specialized proresolving lipid mediators (SPMs), and this would be impaired in some cardiovascular diseases. Among SPMs, resolvins (Rv) have beneficial effects in cardiovascular pathologies, but little is known about their effect on cardiovascular damage in hypertension., [Methods:]: Aorta, small mesenteric arteries, heart, and peritoneal macrophages were taken from C57BL/6J mice, infused or not with angiotensin II (AngII; 1.44 mg/kg/day, 14 days) in presence or absence of resolvin D2 (RvD2) (100 ng/mice, every second day) starting 1 day before or 7 days after AngII infusion., [Results]: Enzymes and receptors involved in SPMs biosynthesis and signaling were increased in aorta or heart from AngII-infused mice. We also observed a differential regulation of SPMs in heart from these mice. Preventive treatment with RvD2 partially avoided AngII-induced hypertension and protected the heart and large and small vessels against functional and structural alterations induced by AngII. RvD2 increased the availability of vasoprotective factors, modified SPMs profile, decreased cardiovascular fibrosis, and increased the infiltration of pro-resolving macrophages. When administered in hypertensive animals with established cardiovascular damage, RvD2 partially improved cardiovascular function and structure, decreased fibrosis, reduced the infiltration of neutrophils, and shifted macrophage phenotype toward a pro-resolving phenotype., [Conclusions]: There is a disbalance between proinflammatory and resolution mediators in hypertension. RvD2 protects cardiovascular function and structure when administered before and after the development of hypertension by modulating vascular factors, fibrosis and inflammation. Activating resolution mechanisms by treatment with RvD2 may represent a novel therapeutic strategy for the treatment of hypertensive cardiovascular disease., This work is supported by SAF2016-80305P (to M. Salaices and A.M. Briones), SAF2016-75021-R (to C. Valenzuela) funded by MCIN/AEI/10.13039/501100011033 and by “ERDF A way of making Europe”; PID2020-116498RB-I00 (to A.M. Briones), PID2019-104366RB-C21 (to C. Valenzuela) funded by MCIN/AEI/10.13039/501100011033, Grant from Comunidad de Madrid (CM) (B2017/BMD-3676 AORTASANA) FEDER— way to build Europe (to M. Salaices); Grant of the Instituto de Salud Carlos III PI21/01048 (to C. Rodríguez); Grant of Consejo Superior de Investigaciones Cientificas: 2019AEP148 (to C. Valenzuela). The study has received funding from the European Union’s Horizon 2020 research and innovation programme under the Marie Sklodowska-Curie grant agreement no. 954798 (to A.M. Briones). R. Rodrigues-Diez was supported by a Juan de la Cierva contract (IJCI-2017-31399). A. de Benito-Bueno is funded by the FPI (BES-2017-080184); P.G. Socuellamos is funded by the FPU (FPU17/02731). J. Dalli is supported by funding from the European Research Council (ERC) under the European Union’s Horizon 2020 research and innovation programme (grant no: 677542) and the Barts Charity (grant no: MGU0343)., Peer reviewed
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Microsomal prostaglandin E synthase-1 is involved in the metabolic and cardiovascular alterations associated with obesity

  • Ballesteros-Martínez, Constanza
  • Rodrigues-Díez, Raquel|||0000-0002-6348-1505
  • Beltrán, Luis M.
  • Moreno-Carriles, Rosa
  • Martínez-Martínez, Ernesto
  • González-Amor, María
  • Martínez-González, José|||0000-0002-3894-7166
  • Rodríguez, Cristina|||0000-0002-6472-5647
  • Cachofeiro, Victoria
  • Salaices, Mercedes
  • Briones, Ana|||0000-0001-8218-5579
Background and Purpose: Microsomal prostaglandin E synthase-1 (mPGES-1) is an inducible isomerase responsible for prostaglandin E production in inflammatory conditions. We evaluated the role of mPGES-1 in the development and the metabolic and cardiovascular alterations of obesity. Experimental Approach: mPGES-1 and mPGES-1 mice were fed with normal or high fat diet (HFD, 60% fat). The glycaemic and lipid profile was evaluated by glucose and insulin tolerance tests and colorimetric assays. Vascular function, structure and mechanics were assessed by myography. Histological studies, q-RT-PCR, and western blot analyses were performed in adipose tissue depots and cardiovascular tissues. Gene expression in abdominal fat and perivascular adipose tissue (PVAT) from patients was correlated with vascular damage. Key Results: Male mPGES-1 mice fed with HFD were protected against body weight gain and showed reduced adiposity, better glucose tolerance and insulin sensitivity, lipid levels and less white adipose tissue and PVAT inflammation and fibrosis, compared with mPGES-1 mice. mPGES-1 knockdown prevented cardiomyocyte hypertrophy, cardiac fibrosis, endothelial dysfunction, aortic insulin resistance, and vascular inflammation and remodelling, induced by HFD. Obesity-induced weight gain and endothelial dysfunction of resistance arteries were ameliorated in female mPGES-1 mice. In humans, we found a positive correlation between mPGES-1 expression in abdominal fat and vascular remodelling, vessel stiffness, and systolic blood pressure. In human PVAT, there was a positive correlation between mPGES-1 expression and inflammatory markers. Conclusions and Implications: mPGES-1 inhibition might be a novel therapeutic approach to the management of obesity and the associated cardiovascular and metabolic alterations.
e_Buah Biblioteca Digital Universidad de Alcalá
Publicación Artículo científico (JournalArticle)

Exploring New Kingdoms: The Role of Extracellular Vesicles in Oxi-Inflamm-Aging Related to Cardiorenal Syndrome

  • Alique Aguilar, Matilde|||0000-0002-7912-1133
The incidence of age associated chronic diseases has increased in recent years. Although several diverse causes produce these phenomena, abundant evidence shows that oxidative stress plays a central role. In recent years, numerous studies have focused on elucidating the role of oxidative stress in the development and progression of both aging and chronic diseases, opening the door to the discovery of new underlying mechanisms and signaling pathways. Among them, senolytics and senomorphics, and extracellular vesicles offer new therapeutic strategies to slow the development of aging and its associated chronic diseases by decreasing oxidative stress. In this review, we aim to discuss the role of extracellular vesicles in human cardiorenal syndrome development and their possible role as biomarkers, targets, or vehicles of drugs to treat this syndrome., Instituto de Salud Carlos III, Sociedad Española de Nefrología, Ministerio de Asuntos Económicos y Transformación Digital, Ministerio de Cultura y Deporte, Ministerio de Ciencia e Innovación, Comunidad de Madrid